MedTrace Logo

Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)

NCT01321320 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2013-10-17

No results posted yet for this study

Summary

The primary hypothesis for this study is that Myostatin and FHL-1 are important in the development of ICUAP and that changes in activity levels of muscle will modify the levels of expression and activity of these proteins.

Conditions

  • Intensive Care Unit Acquired Paresis
  • Muscle Wasting

Interventions

OTHER

Active muscle stimulation

Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • M Polkey · Royal Brompton Hospital and Imperial College

  • Susannah Bloch · Imperial College London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01321320 on ClinicalTrials.gov